{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00314483",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CMCMSC_GVHD012006"
      },
      "Organization": {
        "OrgFullName": "Christian Medical College, Vellore, India",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease",
      "OfficialTitle": "Evaluation of Potential Mesenchymal Stem Cells for the Treatment of Graft Versus Host Disease Following an Allogeneic Stem Cell Transplant"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2007",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2007"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2008",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 12, 2006",
      "StudyFirstSubmitQCDate": "April 12, 2006",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 14, 2006",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 3, 2007",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 6, 2007",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "LeadSponsor": {
        "LeadSponsorName": "Christian Medical College, Vellore, India",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Mesenchymal stem cells (MSC) have been shown to have immunosuppressive properties. Following a bone marrow/peripheral blood stem cell transplant, a proportion of patients develop a condition called 'graft versus host disease' (GVHD). In this condition the transplanted cells recognize the recipient as foreign and bring about an immune-mediated destruction of tissues. The treatment for this condition is to use drugs that will cause immunosuppression. A small subset of these patients develop a severe form of GVHD (Grade III or IV) which, in spite of the best currently available treatment, is associated with eventual death in more than 90% of cases. The investigators propose to use infusions of expanded MSC from the donor to treat this condition. A few reports on this approach have already been published in peer reviewed journals and preliminary results appear to be promising. The investigators are also aware that larger trials have been initiated to study this. After getting written informed consent, the investigators will infuse expanded MSC into patients who develop steroid-resistant GVHD.",
      "DetailedDescription": "A single center non randomized, non blinded Phase I/II clinical trial is proposed to study the role of mesenchymal stem cells (MSC) in the management of steroid refractory graft versus host disease (GVHD) following an allogeneic stem cell transplant.\n\nPatients who develop grade II to IV GVHD following an allogeneic stem cell transplant will be enrolled. MSC will be expanded from the donors of all patients who develop GVHD. Expanded MSC will be infused at a dose of 1-2 million cells/kg in patients who have steroid refractory GVHD.\n\nResponse to therapy will be studied using established criteria for grading GVHD."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft vs Host Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cells",
          "GVHD",
          "Treatment",
          "Steroid refractory GVHD"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "25",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal Stem Cell Infusion"
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Control of GVHD",
            "PrimaryOutcomeTimeFrame": "8 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Infusional toxicity",
            "SecondaryOutcomeTimeFrame": "48 hours"
          },
          {
            "SecondaryOutcomeMeasure": "Risk of relapse",
            "SecondaryOutcomeTimeFrame": "One year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInformed consent obtained from patient and donor\nAny patient who has undergone HLA-matched related allogeneic stem cell transplantation with steroid refractory Grades II-IV acute GVHD\nPrednisolone 2 mg/kg/day (or equivalent doses of methylprednisolone, etc.) for at least one week\n\nExclusion Criteria:\n\nInvasive fungal disease\nActive cytomegalovirus (CMV)/Epstein-Barr virus (EBV)/varicella disease\nRelapsed malignancy",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MinimumAge": "2 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Vikram Mathews, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "91-416-2282891",
            "CentralContactEMail": "vikram@cmcvellore.ac.in"
          },
          {
            "CentralContactName": "Alok Srivastava, MD, FRACP",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "91-416-2282472",
            "CentralContactEMail": "aloks@cmcvellore.ac.in"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Vikram Mathews, MD",
            "OverallOfficialAffiliation": "Christian Medical College, Vellore, India",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Haematology, Christian Medical College",
            "LocationStatus": "Recruiting",
            "LocationCity": "Vellore",
            "LocationState": "Tamil Nadu",
            "LocationZip": "632002",
            "LocationCountry": "India",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Vikram Mathews, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "91-416-2282891",
                  "LocationContactEMail": "vikram@cmcvellore.ac.in"
                },
                {
                  "LocationContactName": "Alok Srivastava, MD, FRACP",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "91-416-2282472",
                  "LocationContactEMail": "aloks@cmcvellore.ac.in"
                },
                {
                  "LocationContactName": "Vikram Mathews, MD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}